Table 1.
Clinical characteristics of patients with neuromyelitis optica (NMO) and multiple sclerosis (MS).
| Clinical characteristics | NMO n = 36 | MS n = 41 | P value | OR (95%) |
|---|---|---|---|---|
| Detectable interferon-alpha | 9/36 | 2/41 | 0.0197 | 6.5 (1.18–64.96) |
| Females | 25 | 33 | 0.2986 | 0.55 (0.17–1.77) |
| Positive anti-AQP4 Ab | 22 | 0 | <0.0001 | NA* |
| ≥3 vertebral segments spinal cord lesion | 30 | 0 | <0.0001 | NA |
| Treatment | 27 | 36 | 0.2358 | 0.42 (0.01–1.59) |
| Interferon-beta | 6 | 27 | <0.0001 | 0.10 (0.03–0.34) |
| Natalizumab | 15 | 9 | 0.0851 | 2.54 (0.85–7.82) |
| Azathioprine | 5 | 0 | 0.0191 | NA |
| Rituximab | 1 | 0 | 0.4675 | NA |
| EDSS; median (range) | 5 (2–9) | 4 (2–9) | 0.046 | NA |
*NA: Nonapplicable.